Aptensio XR

(methylphenidate hydrochloride)
Aptensio XR (methylphenidate hydrochloride); CII
Full Prescribing Information
DailyMed Drug Information
Summary
Aptensio XR is a long-acting methylphenidate CNS stimulant supplied as a multilayer-bead extended-release capsule, approved for ADHD from age 6 with no upper age limit. Each bead carries an immediate-release layer over a controlled-release layer, producing two plasma peaks from one morning dose. The capsule may be opened and sprinkled on applesauce, which is its practical advantage over a swallow-whole osmotic tablet. Schedule II; brand and generic.
Forms & Strengths
Extended-release capsules (multilayer beads, may be opened onto applesauce): 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg
Dosing
Age: >= 6y; no upper limit
Onset: ~ 1 hour
Duration: up to 12 hours
Release Profile: 40% IR / 60% ER via multilayer beads
Initial Dose: 10 mg once daily in the morning
Titration: 10 mg every 7 days
Max Dose: 60 mg/day
Considerations: May be swallowed whole or opened onto applesauce, but never divided, so the ladder moves in whole capsules only.
Pharmacology
Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
Delivery / Release: 40% IR / 60% ER via multilayer beads. Initial peak at about 2 hours, a dip over 4 to 6 hours, then a second peak at about 8 hours.
Metabolism: De-esterified to ritalinic acid, inactive. No CYP pathway. Terminal half-life about 5.1 hours; ~90% recovered in urine, so renal impairment has little effect.
Class Positioning: Racemic, unlike dexmethylphenidate products. Against Concerta it trades an ascending profile for two peaks and can be opened; not interchangeable with Metadate CD or Ritalin LA.
Alcohol: at 40% alcohol, 96% of the dose released within two hours in vitro. Dose dumping is a real risk in an adolescent who drinks.
Indications
ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients ≥ 6 y/o
Off-Label Uses
Narcolepsy (ICD-10: G47.411, G47.419): IR methylphenidate carries this indication, Aptensio XR does not. Extrapolates from the moiety, not the product; limited data.
ADHD in children 4 to under 6 years (ICD-10: F90.x): the label records evidence against. 50% (20 of 39) dropped 10 or more weight percentiles, on exposure 2 to 3 fold higher. Benefits do not outweigh risks.
Treatment-resistant depression augmentation (ICD-10: F32.x, F33.x): adult literature only; insufficient in children.
Cognitive enhancement in youth without ADHD: not an indication and not supported.
Contraindications & Warnings
Boxed Warning: Abuse, misuse and addiction, with overdose and death; risk rises with dose and non-oral routes. Assess abuse risk before prescribing and reassess throughout treatment.
Contraindicated:
Hypersensitivity to methylphenidate; angioedema and anaphylaxis reported
MAOI use, current or within 14 days: hypertensive crisis
Use with caution:
Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid
Pre-existing hypertension: mean rises 2 to 4 mmHg and 3 to 6 bpm, individually larger
Psychotic or bipolar disorder: exacerbation and treatment-emergent mania
Personal or family history of tics or Tourette's syndrome
Significant hyperopia or angle-closure risk: refer to ophthalmology
Substance use disorder in patient or household
Screen before starting:
Cardiac history and exam, plus family history of sudden death; mandatory in section 2.1
Tics or Tourette's, personal and family, with clinical evaluation; also mandatory
Risk factors for a manic episode: depressive symptoms, family history of bipolar disorder or suicide
Abuse and diversion risk in patient and household
Baseline height, weight, blood pressure and heart rate
Drug Interactions
MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days.
Antihypertensives: effectiveness reduced. Increase BP monitoring and adjust the antihypertensive.
Halogenated anesthetics (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold on the day of surgery.
Risperidone: EPS may increase when either dose changes in either direction. Monitor across any titration.
Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only. Counsel on symptoms rather than avoiding.
Alcohol: a formulation interaction, not a pharmacologic one; 96% released within two hours at 40% alcohol. Counsel adolescents explicitly.
Administration
Once daily in the morning. The label asks for a consistent routine with meals rather than fed or fasted.
Swallow whole, or sprinkle the entire contents onto applesauce and eat at once without chewing. Never store a sprinkled dose.
Never divide a capsule. Sprinkling is a swallowing accommodation, not a way to split a dose.
A high-fat meal blunts or removes the second peak and raises Cmax ~28%. An erratic breakfast makes the afternoon erratic.
Missed dose: give the next as scheduled. Never double up or give a first dose late in the day.
Store locked; dispose of unused capsules through a take-back program.
Side Effects
Common, pediatric 6 to 17 y (vs placebo): headache 10.9% vs 8.5%, insomnia 9.8% vs 2.1%, upper abdominal pain 8.2% vs 0%, decreased appetite 4.9% vs 0%, nausea 3.8%, vomiting 3.8%.
Serious:
Sudden death with structural cardiac disease: avoid the drug rather than monitor through it
New psychosis or mania, ~0.1% pooled, including with no psychiatric history: consider discontinuing
Priapism, sometimes surgical, typically after a dose increase and also during drug holidays
Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit
Growth suppression: about 2 cm and 2.7 kg less over 3 years
Acute angle closure glaucoma; new or worsening tics and Tourette's: discontinue if appropriate
Hypersensitivity including angioedema and anaphylaxis
Postmarketing: severe hepatic injury, serotonin syndrome, seizures including grand mal, rhabdomyolysis, pancytopenia
Monitoring & Labs
Cardiovascular: BP and HR at baseline, at each dose change, and every 6 months.
Growth: height, weight and BMI at baseline and every 6 months. Crossing two percentile lines is a labeled trigger to interrupt.
Appetite and sleep: at every visit; both are dose-timing problems before they are drug problems.
Psychiatric and tics: screen for psychosis, mania, aggression and tics at every visit and after each dose increase.
Digital perfusion: inspect fingers and toes at each visit for colour change or ulceration.
Ocular: no routine schedule; refer before starting in significant hyperopia, and at any new eye pain or halos.
Abuse and diversion: at every refill, capsule count, ask about sharing and selling, check the PDMP. A boxed-warning obligation.
Laboratory: none required. Check LFTs only for jaundice, dark urine or unexplained fatigue.
Efficacy stopping rule: discontinue if no improvement after appropriate dose adjustment over one month. A labeled instruction.
Discontinuation & Taper
Can be stopped abruptly at therapeutic doses; the label gives no taper schedule.
Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite. Do not read it as relapse.
Reduce or discontinue for paradoxical worsening or adverse reactions.
Drug holidays are reasonable where growth limits treatment. Priapism has been reported during holidays and on discontinuation.
Pregnancy & Lactation
Pregnancy: human data are limited and insufficient to inform a drug-associated risk. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%. Weigh against untreated maternal ADHD.
Lactation: infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case. Monitor for agitation, poor feeding and reduced weight gain. Not a reason to stop breastfeeding. (LactMed 2025)
Lactation, milk supply: prolactin falls; large doses may interfere before supply is established. (LactMed 2025)
Exposure Registry: National Pregnancy Registry for Psychostimulants, 1-866-961-2388.
Counseling Points
Counsel the family on:
The two-peak profile: a mid-morning dip, then coverage to about 12 hours. Unwarned families read the dip as too low a dose.
Sprinkling onto applesauce, eaten straight away without chewing, never saved for later.
Never splitting a capsule; the ladder moves in whole capsules only.
Keeping breakfast consistent; a fatty breakfast on some days and none on others changes the afternoon.
Moving the largest meal to breakfast and the evening, since appetite suppression peaks midday.
Locked storage; sharing or selling a Schedule II medication is a felony.
For adolescents, that alcohol can release almost the whole capsule at once. Specific to this formulation.
Advise them to call for:
Chest pain, fainting, or a racing heart that does not settle.
New hallucinations, or new suspicious or fearful thinking.
Numbness, coldness, or colour change in the fingers or toes.
A new or markedly worse tic, or a new vocal tic.
Weight loss, or clothes fitting more loosely over a few weeks.
A painful erection lasting more than a few hours, which is a surgical emergency.
Yellowing of the eyes or skin, dark urine, or new eye pain with halos around lights.
References
DailyMed. Aptensio XR (methylphenidate hydrochloride) extended-release capsules prescribing information. Rhodes Pharmaceuticals LLC. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66
LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/
FDA. openFDA National Drug Code Directory, methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22methylphenidate%22
AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/
American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
DEA. Drug scheduling. Methylphenidate is a Schedule II controlled substance. https://www.dea.gov/drug-information/drug-scheduling